Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 732-749
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.732
Table 5 Univariate and multivariate Cox regression analysis for overall survival in gastric cancer patients
Variables

Univariate analysis
Multivariate analysis
HR
95%CI
P value
HR
95%CI
P value
Age in yr1.0241.005-1.0430.013a1.0000.981-1.0200.964
Tumor dimensions in cm
< 3/≥ 33.1431.932-5.112< 0.001a1.3350.778-2.2900.294
Differentiation
Moderate and poor/well0.1440.020-1.0290.0530.6050.073-5.0260.641
Her-2Negative/positive0.5040.206-1.2310.1330.5830.230-1.4790.256
TNM stage< 0.001a< 0.001a
IRefRef
II3.5501.570-8.0270.002a1.7770.665-4.7480.479
III7.0973.290-15.306< 0.001a5.4641.948-15.3270.001a
Operation time in min1.0031.001-1.0060.003a1.0031.000-1.0050.055
Perioperative transfusionNo/yes2.5641.811-3.629< 0.001a1.5171.011-2.2770.044a
CA199 in ng/mLNegative/positive1.9901.347-2.9400.001a1.1840.776-1.8070.433
CEA in ng/mLNegative/positive2.1261.490-3.034< 0.001a1.6051.101-2.3380.014a
Lymph node metastasis rate, %1.0010.991-1.0120.7900.9900.979-1.0020.110
Postoperative complicationNo or minor/major3.4982.434-5.029< 0.001a1.4500.956-2.2000.080
Postoperative chemotherapyNo/yes1.9161.239-2.9630.003a0.6280.357-1.1040.106
Lymphocytes as × 109/L0.4900.347-0.692< 0.001a0.8400.553-1.12750.413
Neutrophils as × 109/L1.2401.152-1.335< 0.001a1.0750.357-1.1040.106
Monocyte as × 109/L7.3932.685-20.351< 0.001a0.7620.188-3.0860.703
Albumin in g/L0.8800.850-0.911< 0.001a0.9690.927-1.0130.164
Fibrinogen in g/L2.0631.792-2.375< 0.001a1.4151.111-1.8030.005a
SIRI1.1901.117-1.267< 0.001a1.0360.764-1.4040.820
AFR0.7270.681-0.776< 0.001a1.0590.858-1.3080.592
SIRI-AFR score< 0.001a
0RefRef
16.0342.964-12.285< 0.001a3.1341.445-6.7970.004a
220.55510.287-41.071< 0.001a5.2392.122-12.935< 0.001a